1. Colombatto P, Romagnoli V, Oliveri F et al (2012) Individualized treatment duration of Peg-IFN + RBV therapy by mathematical prediction of residual HCV infected hepatocytes. In: 19th international symposium on hepatitis C virus and related viruses. Friday, 5 – Tuesday, 9 Oct 2012 Palazzo del Cinema, Lido – Venice. Abstract book p 114
2. Bochud PY, Bibert S, Negro F et al (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 55:980–988
3. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G (2004) Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 9:491–497
4. Chatterjee A, Guedj J, Perelson AS (2012) Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther 17:1171–1182
5. Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, Campa M, Bonino F, Brunetto MR (2003) Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 8:519–530